Close-up of two researchers in lab coats sitting infront of a scientific instrument.

Close-up of scientist wearing a white lab coat.

Making tissue therapeutics possible

Nexocyte™ tissue
therapeutics platform

Fluicell is transforming how we treat disease with one-of-a-kind tissue solutions for regenerative medicine and drug screening.

With the groundbreaking Nexocyte™ platform, based on twenty years of disruptive and patent-protected R&D, we are creating new ways to target serious diseases using precision-engineered biological tissues.

Our transplantable tissues have the potential to help patients living with uncurable tissue damage related to cardiac, pulmonary, metabolic, kidney and other diseases. Fluicell’s first ambitious goal is to develop transplantable tissues to cure type 1 diabetes, impacting the lives of millions of patients.

Nexocyte-generated tissues also enable our world-leading partners to advance their drug-screening capabilities for the development of game-changing medicines.

Latest news

All news & events

See all

June 24, 2025

Selective neuron excitability enables new treatment strategies

Microscopic image of living cell. Parts of the cell have been fluorescently labeled in a crosshatch shape using light.

April 5, 2025

Scientists develop new method to label living cells using light

Microscopy image showing cells being printed using the Biopixlar bioprinter

April 5, 2025

Nexocyte patent granted in the EU

Researcher placing a cell culture dish into the Biopixlar 3D bioprinting platfom.

Platform

Learn more about Nexocyte, Fluicell’s universal tissue production platform, based on our high-resolution single-cell bioprinting technology Biopixlar.

pipeline

Our pipeline consists of products based on our tissue production platform, including tissue-based therapeutics for type 1 diabetes treatment, and cardiac toxicity and kidney disease screening models.

Partner with us!

Learn about what we hope to achieve in partnership with innovation-driven pharmaceutical companies. Have questions or interested in exploring a collaboration? Get in touch.

About our partnerships

what our customers say

Fluicell’s technology is the first of its kind to enable single-cell resolution bioprinting with precision, speed and reproducible accuracy, even in 3D, in a way that was not possible before.

Dr. Luiz Bertassoni, Director Knight Cancer Precision Biofabrication Hub

The BioPen System is one of the best single-cell treatment systems on the market. It is easy-to-use, and gives me beautiful, publication-ready movies.

Dr. Dani Cai, National Institute of Health

The BioPen system provides us with unique data; with it, you are able to see how cell processes are trapped.

Prof. Megan Rizzo, University of Maryland Medical Center

The BioPen product is well designed and works even better than we could have hoped. The team is very reliable with customer support. I would highly recommend purchasing this product.

Dr. Veronica Jove, Rockefeller University

The Dynaflow Resolve system is a very reliable and efficient tool for automated compound application with excellent performance in fast solution exchange.

Dr. Timm Danker, NMI TT